Clinical Trial Search

Primary: Rate of Subjects With a Device and/or Procedure-related SAE. — 7 Participants

Primary: Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) — -16.4; -6.4 Percentage of body weight — p=<0.0001

Primary: Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery — 6.30; 6.26; 6.32; 6.26 Percentage glycosylated hemoglobin — p=<0.0001

Primary: Objective Response Rate (ORR) — 1; 2 Participants

Primary: Number of Participants With 20% Decrease in Phenylalanine Levels From Baseline (Positive Response) — 0; 0; 0 Participants

Primary: Overall Comfort Scores — 59.9; 60.8 unit on a scale

Primary: Number of Patients Who Experienced a Minimum Clinically Important Improvement in Symptoms Over 6 Months of Treatment — 13 Participants

Primary: Safety and Tolerability Will be Measured by Acute NiCord® Infusional Toxicity. — 0; 0; 3; 0 participants

Primary: Change in the Number of Conserved Elements (CEs) With a CD4 or a CD8 T Cell Response From Week 0 to Week 26 — 0; 0; 0 Number of CEs — p=0.137

Primary: Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period of Each Cohort — 1.379; 0.621…

Primary: Comfort on Insertion — 9.2; 9.2 units on a scale

Primary: Spontaneous Stone Passage Using Fisher's Exact Test — 8; 5 Participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 1 Participants

Primary: Opioid Use — 288; 432.5 Oral Morphine Equivalent (mg)

Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…